Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic l…

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT04728893

Phase 4

A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment

This will be a global Phase IV, open-label, randomised study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally \[po\], twice…

Chronic Lymphocytic LeukaemiaModerate to Severe Cardiac Impairment

Estimated

~$10 – $7,500

AstraZenecaNCT06651970

Phase 3

A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (SOUNDTRACK-C1)

The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients w…

Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

Estimated

~$10 – $7,500

AstraZenecaNCT07509151

Phase 1

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other antic…

Chronic Lymphocytic LeukaemiaSmall Lymphocytic LymphomaMantle-cell Lymphoma+2 more

Estimated

~$10 – $7,500

AstraZenecaNCT06564038

Protocol for Transgene Assay Service

The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol…

Non-Hodgkin LymphomaChronic Lymphocytic LeukaemiaMultiple Myeloma

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06357754